Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 2, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcohol Addiction - Overview
Alcohol Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcohol Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcohol Addiction - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Aptinyx Inc
Astellas Pharma Inc
Astraea Therapeutics LLC
Avicanna Inc
AWAKN Life Sciences Corp
BioCorRx Inc
Bioprojet SCR
Ceruvia Lifesciences LLC
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Clearmind Medicine Inc
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Cybin Inc
Eli Lilly and Co
Journey Colab Corp
Kinnov Therapeutics
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrera Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Alcohol Addiction - Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALA-2000 - Drug Profile
Product Description
Mechanism Of Action
arbaclofen ER - Drug Profile
Product Description
Mechanism Of Action
ASP-8062 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
BICX-101 SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
BICX-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BP-1.3656B - Drug Profile
Product Description
Mechanism Of Action
History of Events
brexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
CMND-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CYB-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
D-15 - Drug Profile
Product Description
Mechanism Of Action
DCRALDH-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit Fructokinase for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
History of Events
GET-73 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibudilast - Drug Profile
Product Description
Mechanism Of Action
History of Events
JOUR-001 - Drug Profile
Product Description
Mechanism Of Action
JR-220 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
KNX-100 - Drug Profile
Product Description
Mechanism Of Action
MAP-4343 - Drug Profile
Product Description
Mechanism Of Action
midomafetamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
mifepristone - Drug Profile
Product Description
Mechanism Of Action
History of Events
MQ-221 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nezavist - Drug Profile
Product Description
Mechanism Of Action
History of Events
NYPRG-101 - Drug Profile
Product Description
Mechanism Of Action
NYX-783 - Drug Profile
Product Description
Mechanism Of Action
History of Events
odelepran - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ORP-106 - Drug Profile
Product Description
Mechanism Of Action
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pharmacotherapy for Alcohol Use Disorder - Drug Profile
Product Description
Mechanism Of Action
History of Events
PSIL-002 - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
PT-00114 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PT-150 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RC-132 - Drug Profile
Product Description
Mechanism Of Action
RTI-1395133 - Drug Profile
Product Description
Mechanism Of Action
SKL-10406 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Alcohol Use Disorder - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile
Product Description
Mechanism Of Action
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WIL-1903 - Drug Profile
Product Description
Mechanism Of Action
zolunicant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Featured News & Press Releases
Mar 17, 2022: Clearmind Medicine announces positive results on CMND-100 trials
Feb 28, 2022: MediciNova announces MN-166 (ibudilast) identified as potential beneficial pharmacotherapy for treatment of degenerative cervical myelopathy in Global Spine Journal
Feb 24, 2022: Adial Pharmaceuticals announces completion of last patient, last visit in its ONWARD phase 3 trial of AD04 for the treatment of patients with alcohol use disorder
Feb 22, 2022: MediciNova announces MN-166 (ibudilast) identified as promising pharmacotherapy for alcohol use disorder in drugs
Jan 28, 2022: Clearmind Medicine partners with Dr. Gabor Mate to discuss alcohol use disorder and trauma in a special virtual Event on February 3
Jan 27, 2022: MediciNova receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for the treatment of alcohol use disorder in Europe
Jan 20, 2022: Opiant Pharmaceuticals announces first patient dosed in phase 2 trial of OPNT002, nasal Naltrexone, for alcohol use disorder
Jan 20, 2022: Clairvoyant Therapeutics receives approval in Canada to initiate a world-leading psilocybin trial for treatment of alcohol use disorder
Jan 19, 2022: Awakn Life Sciences signs MOU With MAPS
Jan 11, 2022: Awakn announces positive results from phase II A/B clinical trial
Dec 08, 2021: Cybin confirms scientific advice meeting with UK Medical and Healthcare Products Regulatory Agency for lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder
Nov 16, 2021: Awakn Life Sciences signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a view of increasing access to psychedelic-assisted psychotherapy in the UK
Nov 08, 2021: Cybin announces positive CYB003 data demonstrating significant advantages over oral psilocybin for treatment of mental health
Nov 04, 2021: Awakn Life Sciences announces the findings from phase II A/B study are to be published In American Journal Of Psychiatry
Oct 26, 2021: Clearmind signs development and supply agreement to produce its drug candidate MEAI psychedelic molecule with Aragen Life Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Alar Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Aptinyx Inc, 2022
Alcohol Addiction - Pipeline by Astellas Pharma Inc, 2022
Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, 2022
Alcohol Addiction - Pipeline by Avicanna Inc, 2022
Alcohol Addiction - Pipeline by AWAKN Life Sciences Corp, 2022
Alcohol Addiction - Pipeline by BioCorRx Inc, 2022
Alcohol Addiction - Pipeline by Bioprojet SCR, 2022
Alcohol Addiction - Pipeline by Ceruvia Lifesciences LLC, 2022
Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Clairvoyant Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Clearmind Medicine Inc, 2022
Alcohol Addiction - Pipeline by Colorado Research Partners LLC, 2022
Alcohol Addiction - Pipeline by Confluence Pharmaceuticals LLC, 2022
Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Curemark LLC, 2022
Alcohol Addiction - Pipeline by Cybin Inc, 2022
Alcohol Addiction - Pipeline by Eli Lilly and Co, 2022
Alcohol Addiction - Pipeline by Journey Colab Corp, 2022
Alcohol Addiction - Pipeline by Kinnov Therapeutics, 2022
Alcohol Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Alcohol Addiction - Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Alcohol Addiction - Pipeline by Lohocla Research Corp, 2022
Alcohol Addiction - Pipeline by Mapreg SAS, 2022
Alcohol Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
Alcohol Addiction - Pipeline by Montisera Ltd, 2022
Alcohol Addiction - Pipeline by Naprogenix Inc, 2022
Alcohol Addiction - Pipeline by Neuroepigenix LLC, 2022
Alcohol Addiction - Pipeline by Novo Nordisk AS, 2022
Alcohol Addiction - Pipeline by Omeros Corp, 2022
Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Orphomed Inc, 2022
Alcohol Addiction - Pipeline by Osmotica Pharmaceutical Corp, 2022
Alcohol Addiction - Pipeline by Palisades Therapeutics, 2022
Alcohol Addiction - Pipeline by Pfizer Inc, 2022
Alcohol Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Psilera Inc, 2022
Alcohol Addiction - Pipeline by Sage Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Alcohol Addiction - Pipeline by Sobrera Pharma AB, 2022
Alcohol Addiction - Pipeline by South Plains Biotechnology Inc, 2022
Alcohol Addiction - Pipeline by Syntropharma Ltd, 2022
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Alcohol Addiction - Pipeline by VM Discovery Inc, 2022
Alcohol Addiction - Pipeline by Whan In Pharm Co Ltd, 2022
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, 2022
Alcohol Addiction - Dormant Projects, 2022
Alcohol Addiction - Dormant Projects, 2022 (Contd..1)
Alcohol Addiction - Dormant Projects, 2022 (Contd..2)
Alcohol Addiction - Discontinued Products, 2022
List of Figures
Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
